INTRODUCTION
The serum amyloid A proteins (SAAs) comprise a family of molecules that are apolipoproteins of high-density lipoprotein (HDL) [1] [2] [3] [4] . They can be divided into two groups. The first contains the well-characterized acute-phase SAAs which increase dramatically during inflammatory events [1] [2] [3] . They displace apolipoprotein Al with resultant remodelling of the HDL particle yielding larger particles with a higher hydrated density, and even becoming the major apolipoprotein component of acute-phase HDL [1] [2] [3] [4] . The second group comprises the recently discovered mouse SAA5 [5] and human SAA4 [6] group which are constitutively expressed as minor apolipoproteins associated with HDL during homoeostasis. They are structurally and probably functionally distinct from the acute-phase SAA group. The effect of acute-phase SAA on HDL is still not known, but it seems likely that it equips the HDL particle for an altered role to promote host defence.
In defining the function of acute-phase SAA, one needs to recognize that, as SAA increases in the circulation, there is concomitant cytokine-driven synthesis and extracellular release of non-pancreatic (group-II) secretory phospholipase A2 (sPLA2) [7, 8] . Both SAA and sPLA2 are rapidly induced during inflammatory events [7] [8] [9] [10] with mRNA for both being detectable at 2 h and the resultant proteins similarly produced with respect to time [5, 11] . Whereas acute-phase SAAs are, in practice, only produced in the liver [5, 6] , sPLA2 is produced by a variety of mesenchymal cells that would be present at sites of inflammation [7, 8] . The concentration of sPLA2 can increase hundreds of fold in inflammatory fluids [7, 8, 12] and in the circulation [13, 14] .
The influence of phospholipase activity on HDL is important in the understanding of the function of this particle [15, 16] . In the healthy state, the effect of phospholipase activity on normal HDL has been shown with respect to hepatic lipase [15] [16] [17] . Hydrolysis of surface phospholipid molecules is associated with redistribution of cholesterol from the core to the surface of the HDL particle and increased polar group segmental motion of was found to reduce activity of sPLA2 in a dose-dependent manner, but when acute-phase HDL containing 27 % SAA was tested, it enhanced sPLA2 activity. Immunopurified monospecific antibodies against SAA completely abolished the enhancing activity of SAA and acute-phase HDL. Given the central role of HDL in lipoprotein metabolism, the interaction between HDL, SAA and sPLA2 may account for changes detected in lipoprotein metabolism during the acute phase.
surface phospholipids [15] . The result is a shift in the equilibrium of free cholesterol between HDL and the plasma membrane with an increased net delivery of free cholesterol to the cell by a surface transfer process [15] . Given that the phospholipase activity of hepatic lipase during homoeostasis would be fixed on the surface of hepatocytes, the net result has been postulated to be cholesterol delivery to the liver for excretion, an important part of reverse cholesterol transport [15] [16] [17] .
During the acute phase the situation is dramatically changed. SAA now dominates on the HDL particle and a new phospholipase activity, that of sPLA2, is highly induced by cytokines at inflammatory sites. The interaction between SAAbearing acute-phase HDL and sPLA2 is thus important in the altered HDL function during inflammation. We here report that SAA can promote the activity of sPLA2. Although a number of agents have been described that can block the activity of this enzyme [7, 8] (p = 1.155-1.18 g/ml)] by re-centrifugation of the total HDL fraction into a linear KBr gradient as described previously [18] .
Only HDL3A fractions were used in these studies. Protein concentrations were determined and individual apolipoprotein content was established by pyridine extraction of Coomassie Blue-stained bands from SDS/PAGE as described [4] . Normal HDL3A contained 71% apolipoprotein Al and 29 % apolipoprotein All. Acute-phase HDL3A contained 56 % apolipoprotein Al, 17% apolipoprotein All and 27% acutephase SAA.
Purification of constitutive SM4
SAA4 was isolated from normal human HDL [6] by Rotofor Preparation of acute-phase SM and antibodies to SM Acute-phase HDL3 was delipidated and the SAA separated by molecular-sieve chromatography as described previously [6, 18] . Monospecific rabbit anti-(human SAA) antibodies were raised [18] . (40: 10: 1, by vol.). The mixture was heated for 1 min at 60 'C before addition of 0.66 ml of water and 0.8 ml of heptane. The two phases were allowed to separate and after centrifugation for 10 min at 500 g (1500 rev./min), 0.8 ml of the upper phase was added to 1.0 ml of heptane containing 100 mg of silica gel. The mixture was spun again for 10 min at 500 g and 1.0 ml of the supernatant was used for scintillation counting of '4C-labelled non-esterified palmitic acid. All assays were performed in triplicate [19] .
nhibition studies 
RESULTS

Effect of normal and acute-phase HDL on sPLA2 activity
Normal HDL was found to inhibit the activity of sPLA2 in a dose-dependent manner with an IC50 of 10,ug/ml. With PC/lysoPC liposomes as substrate (Figure 1 ), inhibitory activity was already observed at an HDL concentration of 1 4ug/ml, and a concentration of 100 4tg/ml inhibited sPLA2 activity by 80 % (P < 0.001). when PE/lysoPE liposomes were used as substrate, the inhibition was very similar to that obtained using PC/lysoPC liposomes (52% at 10 ug/ml, 58% at 50 ,ug/ml and 70% at 100 jug/ml). Preincubation with phosphorylcholine (10 1sM) did not abolish the inhibitory activity of normal HDL.
The inhibitory activity of normal HDL was related to the amount of sPLA2 used in the assays. Keeping the HDL concentration constant at 10 ,g/ml, the inhibition of hydrolytic activity by 10 ng of sPLA2 was 59 %, by I00 ng 34% and by 200ng 11%.
As, during the acute phase, newly synthesized and released extracellular acute-phase SAA combines with HDL to form acute-phase HDL, we compared the effects of physiological normal and acute-phase HDL on sPLA2 activity. The former (at a concentration of 15 ,ug/ml) produced 62 % inhibition of sPLA2 activity (P < 0.001) whereas the latter (also at 15 ,g/ml) enhanced sPLA2 activity by 188 % (P < 0.001).
Effect of purified SM on sPLA2 activity
Purified inflammatory SAA enhanced the activity of sPLA2 in a dose-dependent manner (Figure 2 ). With PC/lysoPC liposomes (2: 1, v/v) as substrate, a 135 % increase was seen at an SAA concentration of 3 ,ug/ml, and a concentration of 10 l,g/ml doubled (195 %) sPLA2 activity (P < 0.001). When PC alone was used as substrate, the enhancement was less pronounced with 10 ,sg/ml acute-phase SAA increasing sPLA2 activity to 130 %, 20 ,g/ml to 151 % (P < 0.01) and 50#jg/ml to 185 % (P < 0.001) (results not shown). Liposomes composed of PE/lysoPE (2: 1, v/v) were also hydrolysed but less actively than PC/lysoPC; 10 lg/ml of acute-phase SAA increased sPLA2 activity to 129% and 50 ,tg/ml to 167% (P < 0.00 1). Constitutive SAA in the concentration range 10-50 ,ug/ml did not significantly enhance sPLA2 activity (9-34%) (P>0.05), in either the PC/lysoPC or the PE/lysoPE system (results not shown).
Inhibition of acute-phase-SM-mediated anti-SAA antibody sPLA2 increase by
Acute-phase SAA preincubated with increasing concentrations of anti-SAA antibody gradually lost its sPLA2-enhancing activity (Table 1) . Neither antibody alone nor an irrelevant /?2-microglobulin-anti-fl2-microglobulin complex of similar molecular mass had any effect on sPLA2 activity.
To support the notion that the enhancing activity of acutephase HDL on sPLA2 is caused by the inflammatory SAA associated with HDL, acute-phase HDL3A (25 ,ug/ml) was incubated with immunopurified monospecific anti-SAA antibody. When no antibody was added, the increase in sPLA2 activity by acute-phase HDL3A was 165 % (P < 0.001). Incubation of the HDL3A with 100l,g/ml anti-SAA antibody reduced the enhancement of sPLA2 activity to 12 %; incubation with 200 ,ug/ml antibody abolished the increase completely and actually resulted in inhibition of sPLA2 activity by 29 %. The antibody itself had no effect on sPLA2 activity.
DISCUSSION
During the acute phase, the concentration of the acute-phase protein SAA can increase up to a thousandfold in body fluids [1] . The presence of SAA on HDL remodels the latter [1] and alters its binding characteristics, thereby augmenting its association with macrophages [20] and neutrophils [21] and reducing its affinity for hepatocytes [20] . SAA thus has the potential to dramatically alter HDL function.
Concomitant with the stimulation of SAA production, sPLA2 activity increases markedly under conditions that induce the acute-phase reaction [7, 8] . Circulating sPLA2 activity may increase more than 3000-fold during septic shock [13] . Extremely high sPLA2 activity has been found in patients with malaria [14] , multi-organ dysfunction caused by salicylate poisoning [22] and inflammatory processes such as peritonitis [23] or inflammatory arthritis [24] .
There is a paucity of specific information about the possible link between sPLA2 activity and lipoprotein metabolism, even though a substantial body of evidence exists that this group of lipases alter HDL-mediated lipid flow [15] [16] [17] . It [15, 16] . This process was found to be associated with relocation of cholesterol molecules from the core of HDL to the surface, inducing a shift in equilibrium offree cholesterol between HDL and the plasma membrane [15] . It has also been reported that stimulation of the release of non-esterified fatty acids from PC-labelled human platelets by HDL is probably mediated via activation of membrane-associated PLA2 [25] .
At inflammatory sites there is an enormous increase in fluidphase sPLA2 activity in addition to an alteration of HDL containing SAA (acute-phase HDL). As acute-phase HDL enhances the lipolytic activity of sPLA2 one can envisage a mechanism whereby lipid, particularly cholesterol, would flow from HDL towards cells at such sites. Such lipid delivery might in the short term be of potential benefit during an acute inflammatory event, providing materials for repair of damaged cell membranes.
Given the central role of HDL in lipoprotein metabolism [26] , the interaction of sPLA2 with SAA and HDL could account for some of the changes detected in lipoprotein metabolism during the acute phase. This is of particular relevance for patients with chronic inflammatory diseases such as rheumatoid arthritis, who have prolonged periods of high sPLA2 activity and SAA induction [27, 28] . In these patients a high incidence of atherosclerosis and high mortality from cardiovascular diseases have been reported [29] .
In addition, our findings may be important for events leading to the development of atherosclerotic lesions in the vessel wall. The presence of acute-phase SAA molecules in atherosclerotic lesions in mouse and man has been reported [30, 31] . In situ hybridization studies have indicated SAA production in endothelial cells, macrophage-derived 'foam' cells and vascular smooth-muscle cells in lesions [31] , presumably induced by oxidized lipids present in the milieu [32] . If one considers that vascular smooth-muscle cells are probably a major site of sPLA2 synthesis [11] , the enhancement of sPLA2 activity by SAA at such sites could lead to aberrant lipid delivery and conceivably promote 'foam' cell formation, a key event in atherogenesis.
The finding that constitutive SAA4 had no significant effect on sPLA2 activity suggests that the very conserved region of acutephase SAA between amino acids 35 and 48 could be the active site for promotion of this activity, as constitutive SAAs are the only members of the SAA family with differences in this region [6] . The mechanism by which SAA promotes sPLA2 activity is not known. sPLA2 hydrolyses phospholipids only when they are in a specific spatial orientation. Unperturbed cell-membrane phospholipids for instance resist this activity. It is conceivable that the amphiphilic SAA, when associated with cell membranes, alters their fluidity, making phospholipids accessible to sPLA2-induced hydrolysis. Another possibility is that the SAA region between amino acids 48 and 51, which is similar to the Gly30-XGly32-Gly33 phospholipid-and Ca2+-binding site of PLA2 molecules, is involved. This possibility is lessened by the fact that constitutive SAA [6] has an identical sequence in the above region but does not activate sPLA2.
In conclusion, the present data indicate the existence of a potential mechanism involving SAA-sPLA2 interaction that may significantly alter lipid flow during inflammation.
